【产品介绍】：

生物活性：Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases[1][2][3].
体外研究(In Vitro)：Tegoprazan (1.0 mM and 3.0 mM, 4 h) 通过维持 Caco-2 细胞上皮粘膜的高连接完整性来减少 DSS 诱导的结肠炎[1]。
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Tegoprazan-d6 相关抗体:
ATP7B Antibody (YA2029)
ATP1B1 Antibody (YA2084)
ATP6V1A Antibody (YA2211)
ATPB Antibody (YA2214)
ATP5F1A Antibody (YA2306)
ATP1A2 Antibody (YA2934)
PMCA1 Antibody (YA1676)
ATP1B3 Antibody (YA2201)
ATP5G Antibody (YA2205)
ATP6V0D1 Antibody (YA2208)
ATP1A3 Antibody (YA2462)
ATP4B Antibody (YA2972)
RT-PCR[1]
Cell Line:
Caco-2 cells
Concentration:
1.0 mM and 3.0 mM
Incubation Time:
4 h
Result:
Protected the intestinal epithelial tight junction barrier and inhibits the increase in intestinal permeability.
体内研究(In Vivo)
Tegoprazan (30 mg/kg, 口服, 每天两次, 持续 5 天) 减轻了二硝基苯磺酸 (DNBS) 诱导的结肠长度和结肠损伤的严重程度，以及保护小鼠结肠免受 DNBS 诱导的结肠炎症[1]。
Tegoprazan (3 mg/kg 和 10 mg/kg, 口服, 5 h) 以剂量依赖的方式抑制基础胃酸分泌[2]。
Tegoprazan (0.1, 1 和 10 mg/kg, 口服) 具有剂量依赖性的抗溃疡作用[2]。
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Pylorus-Ligated Rats[2]
Dosage:
3 mg/kg and 10 mg/kg
Administration:
p.o., a single dose
Result:
Inhibited basal gastric acid secretion in a dose-dependent manner and was effective at a single dose in Pylorus-Ligated rats.
Animal Model:
Naproxen-induced acute gastric ulcer rat model[2]
Dosage:
0.1, 1 and 10 mg/kg
Administration:
p.o., a single day or daily for 5 days
Result:
Exerted an antiulcer effect in a dose-dependent manner and was effective at a single dose in naproxen-induced acute gastric ulcer rat model.
Animal Model:
DNBS and Tegoprazan-induced rats[2]
Dosage:
30 mg/kg
Administration:
p.o., twice daily for 5 days
Result:
Reduced mRNA expression levels of proinflammatory cytokines, especially interleukin-17 (IL17) in DNBS and Tegoprazan-induced rats.
分子量：393.42
Formula：C20H13D6F2N3O3
非标记 CAS：942195-55-3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (551 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Takahashi N, Take Y. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther. 2018 Feb;364(2):275-286.
 [Content Brief]